SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Black Monday crash fears surrounding the 1987 anniversary and a recent tech-led pullback dominate discussion, while reports of rising futures fueled relief-rally and short-squeeze hopes. Traders remain divided between expecting a rebound and warning that selling could resume, with major-company earnings adding to market uncertainty.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The prolonged wait for SELLAS to confirm the 80th overall-survival event in its blinded Phase 3 REGAL trial of GPS for AML dominates discussion, alongside a sharp share-price pullback and frustration with company silence. Bulls view the delayed trigger as a possible sign of extended patient survival, while bears question the trial design, disclosure timeline, and prospects for success; those interpretations remain speculative pending data.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances ESMO presentations on lifileucel are driving attention, especially the frontline melanoma combination data and sarcoma results. Traders debate whether the melanoma update adds meaningful new evidence or mainly confirms an older dataset, while many attribute the recent share-price weakness to a broader biotech selloff.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech- and semiconductor-led selloff has fueled concerns that AI spending and financing risks could pressure the broader market, with traders also fixated on Black Monday crash calls. The community is divided between expecting more downside and seeing an oversold rebound, with some dismissing the crash warnings and pointing to futures strength and upcoming big-tech earnings.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas Q3 earnings are the main focus, with traders weighing whether margins and cash flow can hold; the SpaceX-assisted Roadster reveal has added a polarizing side debate, with some praising the technology and others calling it a costly gimmick. Speculation about a TeslaSpaceX merger is also circulating, but no deal is confirmed.

ERock, Inc. operates, designs, and installs distributed generation power systems. The firm primarily serves data centers, utilities, commercial and industrial businesses. The company was founded on 2006 and is headquartered in Houston, TX.

ERock Inc. - Ordinary Shares - Class A

ERock is drawing attention as a potential provider of on-site natural-gas power for AI data centers, with traders focused on its Anthropic and Meta-related contracts and large backlog as evidence of demand. The community is largely bullish on growth and a possible short squeeze, but others are cautious about execution, the CEOs track record, and the stocks volatility.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategys selloff is being tied mainly to MSCIs new index eligibility rules, which could lead to its removal from benchmarks and passive-fund selling; the final decision is still pending. Traders are split between expecting further pressure from potential outflows and viewing the risk as already priced in, while also watching Bitcoins direction and MSTRs sensitivity to it.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Rising crude prices amid conflict and supply-disruption fears around the Strait of Hormuz are lifting Chevron, which traders view as an oil-price proxy. The community is broadly bullish on the momentum and recent highs, though some caution that earnings will also depend on refining margins and that the stock may be overbought.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts withdrawal from the Nscale data-center lease in Essex, reportedly because grid power may not be available until the 2030s, is driving discussion. Traders debate whether it signals prudent capex discipline or broader weakness in AI infrastructure demand; others argue the issue is a local power constraint, not a pullback in demand.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos is drawing attention amid a steep slide to fresh 52-week lows despite reported contract wins, analyst upgrades, and strong defense-drone demand. Traders debate whether the weakness reflects valuation concerns, insider selling, and sector pressure or an oversold buying opportunity, with bulls adding shares as bears warn of further declines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of +8.33% and +31.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of -40.00% and +6.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of -200.00% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +14.55% and +37.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CAMP Expands Its Team as the Race to Unlock Next-Generation RNA Therapeutics Accelerates

Talent is often one of the earliest indicators of a biotechnology company's long-term ambitions. That theme was reinforced this week as CAMP4 Therapeutics (NASDAQ:CAMP) announced an inducement equity award to a newly hired employee under Nasdaq Listing Rule 5635(c)(4), a standard mechanism that allows listed companies to use equity grants as a recruiting incentive for new hires. While modest in size, an option to purchase 8,000 shares, the announcement signals continued investment in building the team behind CAMP4's clinical-stage pipeline.

New Strong Sell Stocks for July 16th

AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of -49.53% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Short Interest in CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Expands By 13.1%

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) was the target of a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 468,369...

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totaling 414,235 shares, a decrease of 14.2% from the March 15th total of 483,060 shares. Based on an average daily trading...

CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to "Strong-Buy" at Rodman & Renshaw

Rodman & Renshaw upgraded CAMP4 Therapeutics to a "strong-buy" rating in a research report on Tuesday...

CAMP4 Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a class of RNA-targeting therapeutics for upregulating gene expression and restoration of healthy protein levels to treat a broad range of genetic diseases. Its lead product candidate is CMP-002. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP4 Therapeutics Corp.

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Calamp Corp.

$CAMP hosted an Analyst Day, detailing its ASCEND Phase 1/2 trial in SYNGAP1 disorder and pipeline progress.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CAMP Calamp Corp.

Fundamentals

Latest CAMP News